Fosamax Cost in Connecticut 2026: Alendronate Prices, Insurance, and Medicaid Coverage

What Does Fosamax Cost in Connecticut in 2026?

Generic alendronate 70 mg runs about $15 per month at most Connecticut retail pharmacies in 2026. Brand-name Fosamax carries a Merck list price near $80 per month, though almost no cash-paying patient needs to pay that figure given the wide availability of generics. Alendronate became generic in 2008, and competition among manufacturers has kept the price low for over 15 years.

The cost spread depends on which pharmacy you use and whether you apply a discount card. GoodRx and similar coupon platforms routinely bring 70 mg weekly alendronate (four tablets, a one-month supply) to $10 to $18 at major Connecticut chains including CVS, Walgreens, Rite Aid, and Stop and Shop. Independent pharmacies sometimes price slightly higher at $18 to $25, though they are more likely to price-match if you ask.

Alendronate belongs to the bisphosphonate class. It binds to bone mineral and inhibits osteoclast-mediated resorption, measurably increasing bone mineral density (BMD) within six to twelve months of consistent weekly dosing [1]. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027), showed alendronate reduced the risk of hip fracture by 47% and clinical vertebral fracture by 55% compared with placebo over three years [2]. That efficacy record is why Connecticut clinicians, telehealth providers, and insurers alike treat alendronate as a first-line agent for postmenopausal osteoporosis and glucocorticoid-induced bone loss [3].

The FDA first approved alendronate (Fosamax) in 1995 for postmenopausal osteoporosis prevention and treatment [4]. The current prescribing label lists the standard treatment dose as 70 mg orally once weekly, taken at least 30 minutes before the first food or drink of the day with plain water only, to maximize absorption and minimize esophageal irritation [4].

How Connecticut Medicaid Covers Alendronate

Connecticut Medicaid (HUSKY Health) covers alendronate with prior authorization. PA is not automatic, but it is generally straightforward for patients who meet standard clinical criteria. A prescriber typically documents a T-score of -2.5 or below on DXA scan, or a T-score between -1.0 and -2.5 with at least one major clinical risk factor such as prior fragility fracture, glucocorticoid use exceeding 5 mg prednisone equivalent daily for three or more months, or a FRAX 10-year major osteoporotic fracture probability at or above 20% [5].

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines define those thresholds explicitly: "Pharmacologic therapy is indicated for patients with osteoporosis (T-score of -2.5 or below) or those at high fracture risk as determined by FRAX or clinical assessment" [6]. That wording maps closely to the criteria Connecticut Medicaid reviewers use when evaluating PA requests.

Once PA is approved, HUSKY Health patients generally pay nothing for the generic, because alendronate sits on Tier 1 or Tier 2 of most state managed-care formularies at a $0 to $3 copay. Approved PA authorizations typically run 12 months, after which the prescriber may need to submit a renewal with updated DXA or fracture-risk documentation [5].

Patients who are denied PA have the right to appeal. Connecticut state law requires Medicaid managed-care organizations to respond to standard PA appeals within 30 days and expedited appeals within 72 hours. If a prescriber believes delay poses a clinical risk, requesting an expedited review is appropriate [7].

Alendronate is also covered under Connecticut's HUSKY D program (Medicaid for low-income adults without dependent children), subject to the same PA pathway. Coverage under Medicare Part D is handled separately and is discussed in the insurance section below [8].

Connecticut Insurance Coverage for Fosamax and Generic Alendronate

Most commercial insurance plans available through Access Health CT (the state's ACA marketplace) and employer-sponsored plans cover generic alendronate on Tier 1 or Tier 2, typically with a $0 to $15 monthly copay. Brand-name Fosamax, when it appears at all, sits on Tier 3 or Tier 4 and may require step therapy, meaning the insurer requires a trial of generic alendronate before it covers the brand [9].

Medicare Part D plans vary. The 2026 Part D standard benefit redesign, which caps out-of-pocket costs at $2,000 annually under the Inflation Reduction Act, has reduced cost exposure for beneficiaries who previously hit the coverage gap [10]. Alendronate's low list price means most Part D enrollees pay $0 to $5 per month after the deductible phase. Patients who remain in the deductible phase early in the year pay the negotiated price, which for alendronate is typically under $15 for a monthly supply [10].

If your plan places alendronate on a higher tier or requires step therapy for brand Fosamax, your prescriber can submit a formulary exception request. The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation, BHOF) recommends that clinicians document "previous treatment failure or intolerance" as the clinical basis for a formulary exception when a patient genuinely cannot tolerate the generic formulation [11].

Merck does not currently maintain an active patient-assistance program specific to Fosamax in 2026, given the drug's generic status. However, third-party discount cards from GoodRx, RxSaver, and Blink Health remain available at Connecticut pharmacies and do not require insurance enrollment. These cards are particularly useful for patients in their Part D deductible phase [12].

Is Compounded Alendronate Legal in Connecticut?

Compounded alendronate prepared by a licensed 503A pharmacy is legal in Connecticut. Section 503A of the federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific compounds based on a valid prescription from a licensed practitioner [13]. Connecticut's Department of Consumer Protection (DCP) licenses and inspects compounding pharmacies operating within the state, and those pharmacies may legally compound alendronate when a prescriber documents a specific clinical rationale.

Common clinical rationales for compounded alendronate include difficulty swallowing standard tablets, documented esophageal dysmotility, or the need for a strength not commercially available. Compounded formulations might include liquid suspensions or capsules at non-standard doses. Some telehealth platforms bundle compounded alendronate with their monthly membership fee, which can bring the effective drug cost to $0 per month for enrolled patients [14].

The FDA distinguishes 503A pharmacies (patient-specific, prescription-required) from 503B outsourcing facilities (bulk compounding for healthcare facilities) [13]. For individual patients in Connecticut, 503A is the applicable pathway. Prescribers should verify that the compounding pharmacy holds a current Connecticut DCP license before directing patients to that facility. The FDA's database of registered 503B outsourcing facilities is publicly searchable, but 503A licensing is tracked at the state level through the DCP [13].

One limitation: compounded drugs are not FDA-approved, and FDA has not evaluated their safety, efficacy, or sterility through the standard new drug application process [13]. For oral alendronate, sterility is not a concern (it is not an injectable), but potency and excipient consistency depend on the compounding pharmacy's internal quality controls.

How to Get the Lowest Alendronate Price in Connecticut

Several concrete options exist for Connecticut patients seeking to minimize their out-of-pocket cost in 2026.

Generic at a discount pharmacy. Costco Pharmacy in Connecticut consistently prices generic alendronate 70 mg (four tablets) at $8 to $12 per month without a coupon. Mark Cuban's Cost Plus Drugs (available for mail delivery to Connecticut addresses) lists alendronate 70 mg at roughly $6 for a four-tablet supply plus a $5 shipping fee, making the effective monthly cost about $11 [15].

GoodRx or RxSaver coupon at retail. Presenting a GoodRx coupon at CVS, Walgreens, or Stop and Shop in Connecticut typically brings the price to $10 to $18. You cannot stack a coupon with insurance, so this option makes sense primarily for uninsured patients, those in the Part D deductible phase, or patients whose insurance tier-cost exceeds the coupon price [12].

Connecticut Medicaid (HUSKY Health). As described above, patients who qualify for HUSKY Health and obtain PA pay $0 to $3 per month. Income thresholds for HUSKY A (families and children) are 201% of the federal poverty level; HUSKY D adults without dependents qualify up to 138% FPL [7].

Telehealth-bundled compounded alendronate. Several telehealth platforms licensed in Connecticut include compounded alendronate at no additional drug cost within their monthly subscription. Monthly subscription fees vary but typically fall between $30 and $75, which may still be less than the total cost of a traditional office visit plus prescription. Confirm the platform's prescriber is licensed in Connecticut and that the compounding pharmacy holds a current DCP license [14].

Patient assistance from generic manufacturers. NeedyMeds.org and RxAssist list manufacturer assistance programs for generic alendronate producers. Eligibility varies, but programs generally target patients with household incomes below 200% to 400% FPL and no drug coverage [15].

Telehealth Prescribing of Alendronate in Connecticut

Connecticut permits telehealth prescribing of alendronate for both new and established patients. The state's telehealth statutes (Connecticut General Statutes Section 19a-906) require that the prescriber conduct a clinically appropriate evaluation, which for osteoporosis management typically includes reviewing prior DXA results, fracture history, and current medications before issuing a prescription [16].

A prescriber does not need to physically examine a patient solely to renew an existing alendronate prescription. For initial prescribing, a thorough video or telephone intake that reviews DXA T-scores, FRAX calculation, renal function (alendronate is contraindicated in patients with creatinine clearance <35 mL/min), and esophageal health history meets the standard of care at most Connecticut telehealth practices [4].

Connecticut's medical board has not issued guidance restricting bisphosphonate prescribing via telehealth specifically. The Connecticut Medical Examining Board follows the general principle that telehealth visits must meet the same standard of care as in-person visits, meaning the prescriber must have enough clinical information to make a sound treatment decision [16].

After a telehealth visit, the prescription can be sent electronically to any Connecticut-licensed pharmacy, including mail-order pharmacies and compounding pharmacies holding a DCP license. Most telehealth platforms integrate e-prescribing directly, so patients receive their alendronate without a physical paper prescription.

Alendronate Dosing and Clinical Context for Connecticut Patients

The standard dose for osteoporosis treatment in postmenopausal women and men is 70 mg once weekly. The prevention dose (for patients with low bone mass but not yet osteoporosis) is 35 mg once weekly. Glucocorticoid-induced osteoporosis in patients taking prednisone 7.5 mg or more daily is treated with 70 mg once weekly in women and men [4].

Alendronate is taken on an empty stomach with 6 to 8 ounces of plain water, and the patient must remain upright (seated or standing) for at least 30 minutes afterward. These instructions are not arbitrary: alendronate's oral bioavailability is roughly 0.6% under ideal conditions; food reduces absorption by an estimated 40% or more [17]. Lying down after dosing substantially raises the risk of esophageal ulceration.

The FIT trial (N=2,027) ran for three years and showed alendronate reduced hip fractures by 47% and clinical vertebral fractures by 55% in women with prior vertebral fracture and low BMD [2]. A separate FIT arm studying women without prevalent vertebral fracture (N=4,432 over 4 years) showed a 36% reduction in clinical fractures overall, though the hip-fracture reduction in that subgroup did not reach statistical significance individually [2]. Both results support the guideline consensus that treatment duration of at least three to five years is appropriate for most patients, with reassessment of fracture risk before continuing beyond five years [3].

Renal function is the primary contraindication: the FDA label explicitly contraindicates alendronate in patients with creatinine clearance <35 mL/min [4]. Before prescribing, Connecticut clinicians should confirm a recent basic metabolic panel or CMP. Calcium and vitamin D adequacy should also be verified, since alendronate cannot deposit calcium into bone if those substrates are insufficient. The BHOF recommends 1,000 to 1 to 200 mg of elemental calcium daily (preferably from food) and 800 to 1 to 000 IU of vitamin D3 daily as co-administration with bisphosphonate therapy [11].

The table below summarizes the cost tiers a Connecticut patient might encounter in 2026, ordered from lowest to highest monthly out-of-pocket cost.

| Access Pathway | Typical Monthly Cost (CT, 2026) | |---|---| | Telehealth-bundled compounded alendronate | $0 (drug cost within subscription) | | HUSKY Health Medicaid (with approved PA) | $0 to $3 | | Cost Plus Drugs mail order | ~$11 (including shipping) | | GoodRx coupon at CT retail pharmacy | $10 to $18 | | Medicare Part D (post-deductible phase) | $0 to $5 | | Standard retail cash-pay (no coupon) | $15 to $25 | | Brand-name Fosamax (no insurance) | ~$80 |

Why Alendronate Remains the First-Line Agent in 2026

Alendronate has more than two decades of post-market safety data and the largest randomized trial base of any oral bisphosphonate. The BHOF position statement states that "bisphosphonates are recommended as first-line pharmacologic therapy for most patients with osteoporosis given their proven anti-fracture efficacy, long-term safety profile, and low cost" [11]. That cost argument is particularly relevant in Connecticut, where the generic cash price sits at roughly $15 per month, compared with $300 to $800 monthly for newer agents such as denosumab (Prolia) or romosozumab (Evenity).

Atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ) are the most frequently raised safety concerns. The absolute risk of AFF is estimated at 3.2 to 50 cases per 100,000 person-years of bisphosphonate use, depending on duration and dose [18]. ONJ risk in patients taking oral bisphosphonates for osteoporosis (as opposed to oncology-dose intravenous bisphosphonates) is estimated at 0.001% to 0.01% [19]. Both risks are orders of magnitude smaller than the morbidity and mortality associated with untreated hip fracture, where 30-day mortality in older adults reaches 5% to 10% and one-year mortality approaches 20% to 30% [20].

Drug holidays, typically defined as stopping alendronate after five years of treatment in lower-risk patients, are supported by the FLEX trial data, which showed that fracture protection persisted for up to five years after discontinuation in patients with femoral neck T-scores above -2.5 at the time of stopping [21]. Patients at higher fracture risk generally should not take a drug holiday without explicit clinician guidance [3].